{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:38:17Z","timestamp":1786747097143,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jcyt.2021.03.003","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T11:13:25Z","timestamp":1619608405000},"page":"724-729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition"],"prefix":"10.1016","volume":"23","author":[{"given":"Anders H.","family":"Kverneland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels Holz","family":"Borch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Granh\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jcyt.2021.03.003_bib0001","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jcyt.2021.03.003_bib0002","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002371-200205000-00007","article-title":"A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma","volume":"25","author":"Dudley","year":"2002","journal-title":"J Immunother"},{"issue":"5594","key":"10.1016\/j.jcyt.2021.03.003_bib0003","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.jcyt.2021.03.003_bib0004","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nri853","article-title":"Maintaining the norm: T-cell homeostasis","volume":"2","author":"Jameson","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.jcyt.2021.03.003_bib0005","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jcyt.2021.03.003_bib0006","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.jcyt.2021.03.003_bib0007","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.jcyt.2021.03.003_bib0008","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jcyt.2021.03.003_bib0009","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ Enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.jcyt.2021.03.003_bib0010","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2021.03.003_bib0011","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00262-011-1182-4","article-title":"Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy","volume":"61","author":"Ullenhag","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jcyt.2021.03.003_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J Immunother"},{"issue":"15","key":"10.1016\/j.jcyt.2021.03.003_bib0013","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-Lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jcyt.2021.03.003_bib0014","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.14470","article-title":"Recent advances in T-cell immunotherapy for haematological malignancies","volume":"176","author":"Rouce","year":"2017","journal-title":"Br J Haematol"},{"issue":"6230","key":"10.1016\/j.jcyt.2021.03.003_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science (80-)"},{"key":"10.1016\/j.jcyt.2021.03.003_bib0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jcyt.2021.03.003_bib0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jcyt.2021.03.003_bib0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk Models for Predicting Chemotherapy-Induced Neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jcyt.2021.03.003_bib0019","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JOP.2012.000815","article-title":"Communicating safe outpatient management of fever and neutropenia","volume":"9","author":"Flowers","year":"2013","journal-title":"J Oncol Pract"},{"issue":"22","key":"10.1016\/j.jcyt.2021.03.003_bib0020","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.18632\/oncotarget.27604","article-title":"Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer","volume":"11","author":"Kverneland","year":"2020","journal-title":"Oncotarget"},{"issue":"Suppl 7A","key":"10.1016\/j.jcyt.2021.03.003_bib0021","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: a systematic review of the literature","volume":"116","author":"Knight","year":"2004","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jcyt.2021.03.003_bib0022","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.jcyt.2021.03.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.jcyt.2021.03.003_bib0024","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jcyt.2021.03.003_bib0025","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jcyt.2021.03.003_bib0026","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2021.03.003_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2015.1100788","article-title":"Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with ipilimumab","volume":"5","author":"Bjoern","year":"2016","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.jcyt.2021.03.003_bib0028","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00262-019-02391-z","article-title":"Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients","volume":"68","author":"Juli\u00e1","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jcyt.2021.03.003_bib0029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2021.03.003_bib0030","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"507","key":"10.1016\/j.jcyt.2021.03.003_bib0031","first-page":"1","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2021.03.003_bib0032","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3324\/haematol.2010.029702","article-title":"Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age","volume":"96","author":"Castermans","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jcyt.2021.03.003_bib0033","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.bmt.1704084","article-title":"A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors","volume":"32","author":"Petersen","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jcyt.2021.03.003_bib0034","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1158\/1078-0432.CCR-16-1692","article-title":"PD-1+ polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer","volume":"23","author":"Donia","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jcyt.2021.03.003_bib0035","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin cancer Res"},{"issue":"17","key":"10.1016\/j.jcyt.2021.03.003_bib0036","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jcyt.2021.03.003_bib0037","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","article-title":"Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients","volume":"16","author":"Besser","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jcyt.2021.03.003_bib0038","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.4049\/jimmunol.1500046","article-title":"Naive T cell maintenance and function in human aging","volume":"194","author":"Goronzy","year":"2015","journal-title":"J immunol"},{"issue":"5","key":"10.1016\/j.jcyt.2021.03.003_bib0039","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10522-008-9138-6","article-title":"The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20\u2013100 years of age","volume":"9","author":"Wikby","year":"2008","journal-title":"Biogerontology"},{"key":"10.1016\/j.jcyt.2021.03.003_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-4933-7-4","article-title":"The effect of ageing on human lymphocyte subsets: comparison of males and females","volume":"7","author":"Yan","year":"2010","journal-title":"Immun Ageing"},{"issue":"1","key":"10.1016\/j.jcyt.2021.03.003_bib0041","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-4933-9-15","article-title":"Hallmarks of human \u201cimmunosenescence\u201d: adaptation or dysregulation?","volume":"9","author":"Pawelec","year":"2012","journal-title":"Immun Ageing"},{"issue":"10","key":"10.1016\/j.jcyt.2021.03.003_bib0042","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.ymthe.2020.06.025","article-title":"Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy","volume":"28","author":"Innamarato","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2021.03.003_bib0043","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1189\/jlb.5MR1116-464R","article-title":"Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation","volume":"102","author":"Koehn","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcyt.2021.03.003_bib0044","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3389\/fimmu.2019.01886","article-title":"Myeloid derived suppressor cells expansion persists after early art and may affect CD4 T cell recovery","volume":"10","author":"Agrati","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2021.03.003_bib0045","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3389\/fimmu.2019.01099","article-title":"Myeloid-derived suppressor cells: not only in tumor immunity","volume":"10","author":"Pawelec","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jcyt.2021.03.003_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19030730","article-title":"The balance of Th17 versus Treg cells in autoimmunity","volume":"19","author":"Lee","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jcyt.2021.03.003_bib0047","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bbmt.2012.11.018","article-title":"Reconstitution of Interleukin-17-Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation","volume":"19","author":"Bahr","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2021.03.003_bib0048","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12185-017-2386-y","article-title":"Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives","volume":"107","author":"ichi","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2021.03.003_bib0049","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921001912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921001912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:44:52Z","timestamp":1761443092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324921001912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1465324921001912"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.03.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}